RxDoctor Payments Data

Stephanie Reeves

Family · Decatur, ALNPI 1396306460

Payments from drug & device makers

$3,475in general payments, 2019–2025

Across 203 payments — averaging $17.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$831
  • Lilly USA, LLC$589
  • AbbVie$402
  • AstraZeneca$229
  • Bayer$179
  • Pfizer$128
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$3,38197%
  • Education$943%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,475 in reported general payments places this provider in the 85th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$14,848
Medicare patients
76
Services billed
263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide107$145,859
OzempicSemaglutide64$87,724
Synjardy XrEmpagliflozin/Metformin Hcl48$57,442
JardianceEmpagliflozin59$56,586
TrulicityDulaglutide32$46,734
RybelsusSemaglutide30$44,097
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$38,755
EliquisApixaban24$21,248
Nurtec OdtRimegepant Sulfate14$19,221
ZubsolvBuprenorphine Hcl/Naloxone Hcl19$16,454
UbrelvyUbrogepant12$15,475
Tresiba Flextouch U-100Insulin Degludec20$15,121
Buprenorphine50$13,586
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl94$13,580
Tresiba Flextouch U-200Insulin Degludec21$12,321

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$589$192,592139 claims
Novo NordiskOzempic, Rybelsus$831$131,82294 claims
Boehringer IngelheimSynjardy Xr, Jardiance$60$114,028107 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$112$50,01975 claims
PfizerEliquis, Nurtec Odt$128$40,47038 claims
AbbVieUbrelvy$402$15,47512 claims
AstraZenecaFarxiga$229$12,03811 claims
MerckBelsomra$85$8,68520 claims
Astellas Pharma US IncMyrbetriq$94$5,25912 claims
Eisai Inc.Dayvigo$16$3,83912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,415 family providers in Alabama.

Other family in Decatur

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →